[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anthracycline-related-cardiotoxicity-in-breast-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anthracycline-related-cardiotoxicity-in-breast-cancer":113},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,78],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100625767",false,"NCT07426913","Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab","Cardiovascular Health Education Via Virtual Reality for Breast Cancer Survivors Receiving Anthracyclines or Trastuzumab - Phase 2","Inclusion Criteria:\n\n* 18 years of age or older\n* Able to speak and read in English\n* Actively receiving Trastuzumab or an anthracycline-based treatment\n* Currently receiving immunotherapy. This includes pembrolizumab and atezolizumab.\n* Diagnosed with stages 0-III Breast Cancer\n\nExclusion Criteria:\n\n\\- History of prior Breast Cancer diagnosis (i.e., not their first breast cancer diagnosis)","FEMALE","18 Years",{"count":18,"type":19},30,"ESTIMATED","INTERVENTIONAL",[22],"NA","The main goal of this study is to test a virtual reality (VR) program, Survivors' Virtual Reality Survivorship Experience (SurviVRSE), designed to help Breast Cancer survivors (n=30) learn about heart health. The aims are to test the usability, feasibility, and acceptability o the intervention. Additionally, follow-up assessments will examine changes in women's cancer therapy related cardiac dysfunction knowledge and heart healthy behaviors (e.g., physical activity).",[25,26,27,28],"Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer","Virtual Reality","Trastuzumab",[30,31,32,33,34,35],"virtual reality","breast cancer","antracyclines","trastuzumab","VCU","Virginia Commonwealth University","RECRUITING","2026-07-01",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":40},"2026-05-20",{"date":44,"type":19},"2027-02-28",{"name":35,"class":46},"OTHER",{"id":48,"slug":4,"hasResults":10,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":77},"100357504","NCT03934905","Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction","Phase II Trial of Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction (CRI18-026)","Inclusion Criteria:\n\n1. Age 18 to 89 years\n2. No prior diagnosis of coronary artery, carotid artery or peripheral artery disease\n3. Not pregnant or breastfeeding (urine pregnancy test will be done if female of childbearing potential)\n4. Breast cancer requiring treatment with DOX-containing regimen above\n5. Women in child bearing age group (18-50 years) will agree to use birth control for duration of study\n6. Study subjects must be willing and able to swallow caplets, up to 8 daily.\n\nExclusion Criteria:\n\n1. Currently on a research study with an investigational drug, or has been on one in the previous 30 days\n2. Pregnant (by urine pregnancy test)\n3. Baseline ejection fraction of less than 50%, evidence of left ventricular hypertrophy or baseline EKG reported as abnormal per cardiologist.\n4. Inability to provide informed consent.\n5. Prior history of chest radiation therapy\n6. Diabetes or Hypertension or prior Myocardial infarction\n7. Trastuzumab patients\n8. Routinely taking vegetable or fruit-containing supplement pills (antioxidant phytochemicals) (daily vitamin pills ok)\n9. Inability to follow up for safety monitoring\n10. Prisoners\n11. Previous or current use of cocaine or any illicit drug\n12. Unable or unwilling to provide blood samples\n13. Taking medications known to have cardiac effects, such as but not limited to, beta blockers, anti-arrhythmic agents, non dihydropyridine calcium channel blockers, ace inhibitors, NSAIDS, diuretic agents.\n14. Unable to follow the protocol\n15. Inability to receive anthracycline due to any reason (underlying baseline cardiac dysfunction due to other reasons, with an EF under 50%)\n16. Patients already taking SFN OTC","ALL","89 Years",{"count":56,"type":19},70,[58,59],"PHASE1","PHASE2","Cardiomyopathy is a major complication of doxorubicin (DOX) chemotherapy, and 10-21% of breast cancer patients receiving DOX experience compromised cardiac function. Recent advancements have increased cancer survivorship but it remains clinically challenging to mitigate the cardiotoxic side effects. Although there are several strategies used to reduce the occurrence and severity of DOX-induced cardiotoxicity, they are not particularly effective. Hence, there is an urgent need to develop new strategies that prevent the cardiotoxic effects of DOX but maintain its potency as a cancer therapy. Because the cellular events responsible for the antitumor activity of DOX and DOX-induced cardiotoxicity are distinctly different, it may be possible to develop therapies that selectively mitigate DOX-induced cardiotoxicity. Thus, the investigators propose to test an adjuvant therapy that combines the phytochemical sulforaphane (SFN) with DOX to attenuate DOX-induced cardiomyopathy. SFN activates the transcription factor Nrf2 and induces defense mechanisms in normal cells. Furthermore, SFN inhibits carcinogenesis and metastases and enhances cancer cell sensitivity to DOX, seemingly through Nrf2-independent mechanisms. SFN has also been tested in several clinical trials, although never together with DOX. Our early animal studies suggest that by activating Nrf2, SFN selectively protects the mouse and rat from DOX cardiotoxicity, enhances survival and enhances the effects of DOX on cancer growth in a rat breast cancer model. The investigators suspect that SFN affects DOX metabolism in cancer cells to enhance tumor regression, or it may synergistically activate other key antitumor mechanisms. Hence, SFN may improve the clinical outcome of cancer therapy by (1) attenuating DOX cardiotoxicity and (2) enhancing the effects of cancer treatment on the tumor. Our hypothesis is that SFN protects the heart from DOX-mediated cardiac injury without altering the antitumor efficacy of DOX. In Aim 1, the investigators will conduct an early-phase clinical trial to determine if SFN is safe to administer to breast cancer patients undergoing DOX chemotherapy. In Aim 2, the investigators will determine if SFN decreases DOX-induced inflammatory responses and enhances Nrf2- and SIRT1-target gene expression in breast cancer patients. Notably, transcript and protein signatures in peripheral blood mononuclear cells (PBMCs) can predict cardiac function in patients undergoing DOX chemotherapy for breast cancer. The investigators will also determine if SFN\u002FDOX treatment activates Nrf2- and SIRT1-dependent gene expression, alters the levels of biomarkers for presymptomatic DOX-cardiotoxicity and mitigates the generation of cardiotoxic metabolites in PBMCs and plasma. These studies will facilitate the development of SFN co-treatment as a strategy to enhance the efficacy and safety of DOX cancer therapy.",[26],[63,64,65,66,67],"doxorubicin","sulforaphane","cardiotoxicity","nrf2","heart","2026-06-24",{"date":70,"type":40},"2026-06-29",{"date":72,"type":40},"2022-06-01",{"date":74,"type":19},"2029-06-01",{"name":76,"class":46},"Texas Tech University Health Sciences Center",1,{"id":79,"slug":4,"hasResults":10,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":20,"phases":87,"briefSummary":89,"conditions":90,"keywords":93,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100612487","NCT07254221","Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy","ROSUBREAST","Inclusion Criteria:\n\n* Female individuals with ≥18 years of age\n* Documented breast cancer diagnosis based on imaging and pathology findings\n* Scheduled to receive the first time anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Baseline LVEF \\\u003C 50%\n* Prior Statin use or Statin use is indicated based on guidelines\n* history of congestive heart failure (CHF) or cardiomyopathy\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of oral cyclosporine\n* Metastatic invasion of cancer to other organs\n* Previous cycles of chemotherapy\n* Any contraindication for statin use",{"count":86,"type":19},400,[88],"PHASE4","This study, called \"ROSUBREAST\", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.",[91,25,26,92],"Anthracycline-induced Cardiac Toxicity","Anthracycline-induced Cardiotoxicity",[94,95,96,97,98,99,65,100,101],"Breast cancer","rosuvastatin","statin therapy,","cancer-related treatment cardiac dysfunction","anthracycline induced cardiomyopathy","cardiac dysfunction","chemotherapy","anthracycline","NOT_YET_RECRUITING","2025-12-03",{"date":105,"type":40},"2025-12-10",{"date":107,"type":19},"2026-02-01",{"date":109,"type":19},"2028-04-21",{"name":111,"class":46},"Shiraz University of Medical Sciences",7,""]